Pixium Vision (PA:PIX) has announced it has successfully implanted the first patient with its second-generation epi-retinal implant, Iris II. This is the first patient enrolled in a study of up to 10 patients with retinitis pigmentosa or other retinal dystrophies. Pixium filed for CE mark approval in December 2015 for Iris II.
First perception of light
The pivotal trial for Iris II recently enrolled and successfully implanted its first patient. Iris II is an epi-retinal implant that uses signals from a video camera to stimulate the nerves in the retina to simulate the image captured by the camera. The implant was made into a 58-year-old retinitis pigmentosa patient, who reported first perception of light after many years in the darkness; the patient will now receive training to learn how to interpret the light signals.
To read the entire report Please click on the pdf File Below